A gentle nasal swab, similar to a COVID test, may one day help doctors detect Alzheimer’s disease before memory problems begin. Duke researchers say the approach could open a new window for earlier diagnosis and treatment.
A quick nasal swab, similar to the ones used for COVID-19 testing, may help doctors detect Alzheimer’s disease years before memory loss and confusion appear.
In a new study published in Nature Communications, Duke Health researchers report that a gentle swab high inside the nose can capture living nerve and immune cells that carry early biological signals of Alzheimer’s. The approach could offer a simple outpatient test to flag people at risk while there is still time to protect the brain.
Alzheimer’s disease affects millions of people worldwide and is usually diagnosed only after thinking and memory problems become obvious. By then, much of the damage in the brain has already occurred, and current treatments have limited power to slow the disease.
The Duke team set out to find a way to see the disease earlier.
“We want to be able to confirm Alzheimer’s very early, before damage has a chance to build up in the brain,” corresponding author Bradley J. Goldstein, a professor in the departments of Head and Neck Surgery & Communication Sciences, Cell Biology and Neurobiology at Duke University School of Medicine, said in a news release. “If we can diagnose people early enough, we might be able to start therapies that prevent them from ever developing clinical Alzheimer’s.”
The researchers focused on the upper part of the nasal cavity, where the cells that detect smell live. This region is one of the few places in the body where nerve cells that connect directly to the brain are accessible from the outside.
In the study, clinicians applied a numbing spray and then guided a tiny brush into this area to collect cells. The procedure took just a few minutes in an outpatient setting.
Back in the lab, scientists analyzed the collected cells one by one, looking at which genes were turned on or off. That gene activity pattern offers a snapshot of what is happening inside the cells and, by extension, may reflect changes occurring in the brain.
The team compared nasal samples from 22 participants, including people with early signs of Alzheimer’s in lab tests, people with diagnosed Alzheimer’s, and people without the disease. They measured the activity of thousands of genes across hundreds of thousands of individual cells, generating millions of data points.
From this data, the researchers identified clear differences in nerve and immune cells between those with early or clinical Alzheimer’s and those without the disease. They then combined these signals into a single gene-based score from the nasal tissue.
That combined score correctly distinguished early and clinical Alzheimer’s cases from healthy controls about 81 percent of the time, according to the study.
Importantly, the nasal swab picked up changes even in people who showed lab-based signs of Alzheimer’s but did not yet have symptoms. That suggests the test could help identify at-risk individuals before memory problems begin.
Today’s blood tests for Alzheimer’s look for proteins and other markers that tend to appear later in the disease process. By contrast, the nasal swab captures living nerve and immune cells that are directly connected to the brain, offering a more immediate view of disease-related changes.
First author Vincent M. D’Anniballe, a student in the Medical Scientist Training Program at Duke, noted the ability to sample living brain-related tissue is a major shift for the field.
“Much of what we know about Alzheimer’s comes from autopsy tissue,” he said in the news release. “Now we can study living neural tissue, opening new possibilities for diagnosis and treatment.”
For families affected by Alzheimer’s, the promise of earlier detection is deeply personal.
Mary Umstead volunteered for the study in honor of her sister, Mariah, who was diagnosed with young-onset Alzheimer’s at age 57 after years of subtle symptoms.
“When the opportunity came along to be part of a research study, I just jumped at it because I would never want any family to have to go through that kind of loss that we went through with Mariah,” she said. “I would never want any patient to go through what she went through either.”
Her story reflects a common experience: families often notice changes long before a formal diagnosis, leaving a painful gap where earlier answers and support might have made a difference.
While the new nasal swab test is still in the research stage, it illustrates how scientists are rethinking Alzheimer’s detection. Instead of waiting for memory tests or brain scans to show clear damage, they are looking for subtle cellular and molecular changes that emerge years earlier.
The Duke team, working with the Duke & UNC Alzheimer’s Disease Research Center, is now expanding the study to larger groups of people. They also plan to explore whether repeated nasal swabs could help track how well treatments are working over time, potentially giving doctors a faster way to see if a therapy is helping.
Duke has filed a U.S. patent related to the nasal swab approach, a sign that the researchers see potential for future clinical use if further studies confirm the findings.
More broadly, the work adds to a growing push in Alzheimer’s research to move from late-stage diagnosis to early detection and prevention. Scientists hope that by identifying people at risk sooner, they can test new drugs, lifestyle changes or other interventions when the brain is more resilient.
For now, the nasal swab remains an experimental tool. But the idea that a simple, painless procedure in a clinic could reveal what is happening deep in the brain offers a hopeful glimpse of what Alzheimer’s care might look like in the years ahead.
Source: Duke Health